Purepac to become Faulding through subsidiary consolidations.
PUREPAC TO MERGE WITH FAULDING U.S. SUBSIDIARIES, CHANGE NAME to Faulding, Inc. in a series of transactions announced Aug. 10. Generic drug maker Purepac, which is 64%-owned by the Australian manufacturer Faulding, has agreed to acquire: Faulding Pharmaceuticals, which is Faulding's U.S. injectables marketing arm; Faulding Medical Devices, which is developing shell glass vial and device technologies; and Faulding Puerto Rico, which owns products and manufacturing facilities in Puerto Rico that formerly belonged to DuPont Merck.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth